227 related articles for article (PubMed ID: 12449043)
1. [The role of gemcitabine in hematology].
Dumontet C
Bull Cancer; 2002 Aug; 89 Spec No():S123-6. PubMed ID: 12449043
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine in hematologic malignancies.
Nabhan C; Krett N; Gandhi V; Rosen S
Curr Opin Oncol; 2001 Nov; 13(6):514-21. PubMed ID: 11673693
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma.
Offidani M; Mele A; Corvatta L; Marconi M; Malerba L; Olivieri A; Rupoli S; Alesiani F; Leoni P
Leuk Lymphoma; 2002 Jun; 43(6):1273-9. PubMed ID: 12152996
[TBL] [Abstract][Full Text] [Related]
4. [Chemotherapy using gemcitabine hydrochloride for malignant lymphoma].
Asou H; Maeda K; Takeuchi K; Kiyosawa K; Taniai H
Gan To Kagaku Ryoho; 2013 Nov; 40(11):1489-95. PubMed ID: 24231701
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and its combinations in the treatment of malignant lymphoma.
Chau I; Watkins D; Cunningham D
Clin Lymphoma; 2002 Sep; 3(2):97-104. PubMed ID: 12435288
[TBL] [Abstract][Full Text] [Related]
6. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study.
Mi M; Zhang C; Liu Z; Wang Y; Li J; Zhang L
Medicine (Baltimore); 2020 Dec; 99(49):e23412. PubMed ID: 33285732
[TBL] [Abstract][Full Text] [Related]
8. [Gemcitabine in the treatment of relapsed or refractory non-Hodgkin's lymphoma].
Ma S; Sheng X; Luo R; Li A
Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):619-20. PubMed ID: 12667341
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma.
Yang SH; Lin ZZ; Kuo SH; Cheng AL
Am J Hematol; 2009 Jul; 84(7):457-9. PubMed ID: 19484737
[No Abstract] [Full Text] [Related]
10. A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.
Manegold C; Drings P; von Pawel J; Ricci S; Dornoff W; van Walree N; ten Bokkel Huinink W; Chemaissani A; Stahel P; Bergman B; Wagenius G; Sederholm C; Mattson K; Liippo K; Kellokumpu-Lehtinen P
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-13-S8-17. PubMed ID: 9207310
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine-Based Treatment in Poor-Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma--a Multicenter Polish Experience.
Rybka J; Jurczak W; Giza A; Paszkiewicz-Kozik E; Kumiega B; Drozd-Sokołowska J; Butrym A; Kuliczkowski K; Wróbel T
Adv Clin Exp Med; 2015; 24(5):783-9. PubMed ID: 26768628
[TBL] [Abstract][Full Text] [Related]
12. [Role of gemcitabine in the treatment of other malignant tumors].
Clippe C; Ligneau B; Trillet-Lenoir V
Bull Cancer; 2002 Aug; 89 Spec No():S120-2. PubMed ID: 12449042
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma.
Zlotnick M; Avigdor A; Ribakovsky E; Nagler A; Kedmi M
Acta Haematol; 2019; 141(2):84-90. PubMed ID: 30630175
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety evaluation of gemcitabine combined with oxaliplatin in lymphoma patients after failure of multiple chemotherapy regimens].
Yang J; Shi Y; He X; Zhou S; Dong M; Liu P; Zhang C; Qin Y; Yang S; Gui L
Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):137-40. PubMed ID: 24796464
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine for relapsed or resistant lymphoma.
Savage DG; Rule SA; Tighe M; Garrett TJ; Oster MW; Lee RT; Ruiz J; Heitjan D; Keohan ML; Flamm M; Johnson SA
Ann Oncol; 2000 May; 11(5):595-7. PubMed ID: 10907954
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine: new indication. Relapsed ovarian cancer: simply more toxic. Increases haematologic toxicity but not overall survival.
Prescrire Int; 2009 Aug; 18(102):156. PubMed ID: 19746525
[No Abstract] [Full Text] [Related]
18. Gemcitabine--a major advance?
Thomas A; Steward WP
Ann Oncol; 1998 Dec; 9(12):1265-7. PubMed ID: 9932153
[No Abstract] [Full Text] [Related]
19. [Gemcitabine and urogenital tumors].
Culine S
Bull Cancer; 2002 Aug; 89 Spec No():S102-6. PubMed ID: 12449039
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: a Hoosier Oncology Group study.
Einhorn LH
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-24-S8-26. PubMed ID: 9207312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
